Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368222 | 0.83 | MEN1 (1.00) | ARPGRMEN1KMT2APKM | |
| SCHEMBL19065076 | 0.82 | AR (0.77) | ARPGRMEN1KMT2ANPC1 | |
| SCHEMBL2665022 | 0.81 | KMT2A (0.73) | PGRMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL17847424 | 0.81 | CA12 (0.70) | ARPGRMEN1KMT2ANPC1 | |
| SCHEMBL5380382 | 0.80 | MEN1 (0.77) | ARPGRMEN1KMT2ANPC1 | |
| SCHEMBL3556205 | 0.80 | MAPT (0.64) | MEN1KMT2AHPGDTDP1MAPT | |
| SCHEMBL21693592 | 0.78 | KMT2A (0.73) | PGRMEN1KMT2ANPC1HPGD | |
| SCHEMBL3562602 | 0.78 | ALDH1A1 (0.53) | ARPGRMEN1KMT2AHPGD | |
| SCHEMBL5378751 | 0.78 | MEN1 (0.72) | ARPGRMEN1KMT2ANPC1 | |
| SCHEMBL8752429 | 0.78 | AR (0.75) | ARPGRMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | AR 88/4885PGR 347/4885MEN1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.